Selinexor and Backbone Treatments of Multiple Myeloma Patients
Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.3
6 insiders sold shares within a month
Since May 14, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 300 (planned)
- Started
- Oct 2015
- Main results expected
- Apr 2027
- Fully finished
- Apr 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD)
Measured over: 12 months
Phase 1 (Dose-escalation): Recommended Phase-2 dose (RP2D)
Measured over: 12 months
Phase 1 (Dose-escalation): Maximum Plasma Concentration (Cmax) of Selinexor
Measured over: Pre-dose, 1 hour, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post-dose on Day 1 (without clarithromycin) and Day 8 (with clarithromycin)
Phase 1 (Dose-escalation): Area Under the Concentration-time Curve From Time Zero to the Last Non-zero Concentration (AUC0-t) of Selinexor
Measured over: Pre-dose, 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post-dose on Day 1 (without clarithromycin) and Day 8 (with clarithromycin)
Phase 1 (Dose-escalation): Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) (AUC0-inf)
Measured over: Pre-dose, 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post-dose on Day 1 (without clarithromycin) and Day 8 (with clarithromycin)
Phase 2 (Expansion): Overall response rate (ORR)
Measured over: 12 months
Phase 2 (Expansion): Duration of response (DOR)
Measured over: 12 months
Phase 2 (Expansion): Clinical Benefit Rate (CBR)
Measured over: 12 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.3, since 2026-05-14, fades (half-life)
Raw record changes
- none yet
Trial ID NCT02343042 · record last updated 2026-07-15 · checked 2026-11-09 15:47 UTC